The Progression of Inorganic Nanoparticles and Natural Products for Inflammatory Bowel Disease
Overview
Authors
Affiliations
There is a growing body of evidence indicating a close association between inflammatory bowel disease (IBD) and disrupted intestinal homeostasis. Excessive production of reactive oxygen species (ROS) and reactive nitrogen species (RNS), along with an increase in M1 proinflammatory macrophage infiltration during the activation of intestinal inflammation, plays a pivotal role in disrupting intestinal homeostasis in IBD. The overabundance of ROS/RNS can cause intestinal tissue damage and the disruption of crucial gut proteins, which ultimately compromises the integrity of the intestinal barrier. The proliferation of M1 macrophages contributes to an exaggerated immune response, further compromising the intestinal immune barrier. Currently, intestinal nanomaterials have gained widespread attention in the context of IBD due to their notable characteristics, including the ability to specifically target regions of interest, clear excess ROS/RNS, and mimic biological enzymes. In this review, we initially elucidated the gut microenvironment in IBD. Subsequently, we delineate therapeutic strategies involving two distinct types of nanomedicine, namely inorganic nanoparticles and natural product nanomaterials. Finally, we present a comprehensive overview of the promising prospects associated with the application of nanomedicine in future clinical settings for the treatment of IBD (graphic abstract). Different classes of nanomedicine are used to treat IBD. This review primarily elucidates the current etiology of inflammatory bowel disease and explores two prominent nanomaterial-based therapeutic approaches. First, it aims to eliminate excessive reactive oxygen species and reactive nitrogen species. Second, they focus on modulating the polarization of inflammatory macrophages and reducing the proportion of pro-inflammatory macrophages. Additionally, this article delves into the treatment of inflammatory bowel disease using inorganic metal nanomaterials and natural product nanomaterials.
Huang Y, Cai H, Liu H, Wang L, Feng G, Ding Z J Nanobiotechnology. 2025; 23(1):188.
PMID: 40055678 PMC: 11889847. DOI: 10.1186/s12951-025-03240-1.
Tumor-Associated Macrophages: Key Players in the Non-Small Cell Lung Cancer Tumor Microenvironment.
Lv T, Fan R, Wu J, Gong H, Gao X, Liu X Cancer Med. 2025; 14(3):e70670.
PMID: 39927632 PMC: 11808749. DOI: 10.1002/cam4.70670.
Ran X, Li Y, Ren Y, Chang W, Deng R, Wang H Cell Death Dis. 2025; 16(1):20.
PMID: 39809743 PMC: 11733159. DOI: 10.1038/s41419-025-07338-0.
Cell Membrane-Coated Nanotherapeutics for the Targeted Treatment of Acute and Chronic Colitis.
Li S, Chen L, Wu T, Wu J, Yang H, Ju Q Biomater Res. 2024; 28:0102.
PMID: 39512421 PMC: 11542430. DOI: 10.34133/bmr.0102.
Redox-manipulating nanocarriers for anticancer drug delivery: a systematic review.
Meng X, Shen Y, Zhao H, Lu X, Wang Z, Zhao Y J Nanobiotechnology. 2024; 22(1):587.
PMID: 39342211 PMC: 11438196. DOI: 10.1186/s12951-024-02859-w.